Welcome to our dedicated page for Immuron SEC filings (Ticker: IMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immuron Limited (NASDAQ: IMRN, ASX: IMC) is a foreign private issuer that reports to the U.S. Securities and Exchange Commission primarily through Form 20‑F annual reports and Form 6‑K current reports. This SEC filings page on Stock Titan centralizes those documents and pairs them with AI‑generated summaries to help readers understand the regulatory information associated with Immuron’s biopharmaceutical business.
Recent Form 6‑K filings furnished by Immuron reference Australian Securities Exchange announcements such as applications for quotation of securities, cleansing notices, CEO addresses, annual general meeting results, changes of director interests, changes of share registry, and clinical and regulatory milestones including FDA approval of the IMM‑529 Investigational New Drug application. These filings provide context on capital management, governance decisions and progress in the company’s clinical programs for Travelan/IMM‑124E, IMM‑529 and IMM‑986.
On this page, you can review Immuron’s 20‑F annual report for a comprehensive description of its operations, risk factors and financial statements, and browse 6‑K current reports that capture material information first released to the Australian Securities Exchange. Where applicable, Stock Titan also surfaces Form 4 and related insider transaction disclosures that are filed in connection with changes in director or executive holdings, as referenced in Immuron’s 6‑K exhibits.
Stock Titan’s AI features highlight key points from lengthy filings, explain technical sections in plain language, and help you locate items such as clinical trial updates, securities issuances and shareholder meeting outcomes. This makes it easier to track how Immuron’s regulatory disclosures align with its strategy in orally delivered targeted polyclonal antibodies and its commercial and clinical activities.
Immuron Limited reports HY26 global sales revenue of A$4.2 million, up 5% on the prior year, driven by strong Travelan and ProIBS demand. Australian sales rose to A$3.3 million, up 13%, while North American revenue was A$0.9 million, down 18%, though U.S. sales within that increased 17%.
Cash was A$10.0 million at 31 December 2025, up A$7.2 million from 30 June 2025, with EBITDX (ex-R&D) of -A$1.1 million. The company is resetting its strategy by seeking partners for its clinical assets IMM-124E for traveler’s diarrhea and IMM-529 for recurrent C. difficile infection, aiming to have licensees fund further development and commercialization while Immuron focuses on over-the-counter products Travelan and ProIBS.
Immuron Limited reported half-year 2026 revenue of A$4.18 million, up about 5% from the prior year, driven mainly by its Travelan hyperimmune products. Australia led with A$3.19 million in Travelan sales and 11% growth, while U.S. Travelan sales rose 17% to A$0.85 million; Canada declined.
The group’s net loss narrowed to A$1.92 million from A$2.49 million, with gross profit of A$2.65 million and a 63% margin. Hyperimmune products generated operating profit of A$0.98 million, helping lift net assets to A$13.08 million and cash to A$9.99 million after equity raises.
Strategically, Immuron gained FDA approval of an Investigational New Drug application for IMM-529 targeting Clostridioides difficile infection and is positioning the candidate for a Phase 2 trial aimed at recurrent cases. The company also launched PROIBS for irritable bowel syndrome in Australia and continues military-linked collaborations on new oral therapeutics for Campylobacter and Shigella.
Immuron Limited reported receiving an R&D Tax Incentive refund of A$1,121,885 from the Australian Government for eligible research and development activities conducted in the financial year ending June 30, 2025. This government program refunds 43.5% of eligible R&D expenditure.
The company describes this as non‑dilutive funding, helping it invest in growing sales and profitability while preserving financial flexibility. Immuron is planning profitability growth of its Hyper-Immune products and, together with cost reduction initiatives, is targeting improved EBITDX (ex‑R&D) in FY26.
Immuron Limited filed a Form 6-K to furnish results of its 2026 Extraordinary General Meeting. Shareholders passed all resolutions in the Notice of Meeting by poll.
Two ordinary resolutions ratifying prior issues of shares under ASX Listing Rules 7.1 and 7.1A were carried, with poll votes of 63.95% for and 36.05% against on each resolution.
Immuron Limited reported leadership changes effective 9 February 2026, with Mr Phillip Hains resigning as Chief Financial Officer and Company Secretary after serving since 2013. The company appointed Olga Smejkalova as Company Secretary and Aaron Laurita as Chief Financial Officer on the same date.
The announcement notes Ms Smejkalova will handle ASX Listing Rule communications and highlights both appointees’ governance, finance and commercial experience. The filing also reiterates Immuron’s focus on orally delivered targeted polyclonal antibodies and provides background on its Travelan product for travelers’ diarrhea.
Immuron Limited provides an update via an investor presentation highlighting strong growth in its over-the-counter products and progress in its R&D pipeline. For FY 2025, global sales revenue reached
The company reports continued Travelan sales growth, with FY 2026 first-half global net sales of
Immuron Limited reports unaudited first-half global sales of Travelan® of AUD$4.2 million, up 5% on the prior comparative period. Second-quarter sales were AUD$2.2 million, 11% higher than the prior quarter, reflecting continued momentum.
In Australia, H1 sales reached AUD$3.3 million, up 13% on the prior period, with Q2 at AUD$1.7 million, also up 11%. Growth was driven by digital and social media marketing, stronger in‑store promotion, new store rollouts, and increased South East Asian travel, partially offset by a one‑off stock reduction by a major pharmacy group. Immuron also launched its new product ProIBS® into the Australian market.
In the U.S., H1 sales were AUD$0.9 million, up 17% on the prior period, aided by Amazon store improvements and expanded social media marketing. In Canada, H1 sales were AUD$56 thousand, down 85% on the prior period due to prior pipeline fill, but Q2 sales of AUD$42 thousand rose 191% on the prior quarter, with further distribution planned, including a Travelan® launch into Jean Coutu pharmacies in 3QFY26.
Immuron Limited furnished a Form 6-K highlighting that its Chief Executive Officer, Steven Lydeamore, will present virtually at the Emerging Growth Conference on Thursday, January 22, 2026, from 2:40 pm to 2:50 pm U.S. Eastern Time. The filing provides a registration link for live attendance and notes that an archived webcast will be available after the event.
The content also describes Immuron as an Australian biopharmaceutical company focused on orally delivered targeted polyclonal antibodies for infectious diseases. It outlines key products and programs including Travelan for travelers’ diarrhea, IMM-529 for recurrent Clostridioides difficile infection, and the distributed product ProIBS for irritable bowel syndrome symptoms.
Immuron Limited has called an Extraordinary General Meeting for 12 February 2026 to seek shareholder approval to ratify prior share issues made under its at-the-market (ATM) funding facility. Shareholders are being asked to approve two resolutions ratifying the issue of 28,278,923 shares under ASX Listing Rule 7.1 and 26,821,997 shares under Listing Rule 7.1A, for a total of 55,100,920 fully paid ordinary shares. The shares were issued in several ATM drawdowns in October, November and December 2025 at prices between $0.07560 and $0.08860 per share.
The company previously filed a Form F-3 and ATM prospectus in the United States allowing it to raise up to US$15 million over three years, and later extended the ATM facility by an additional approximate aggregate offering price of US$2,847,954. Funds raised are intended to support working capital and various projects. The board unanimously recommends that shareholders vote in favour of both ratification resolutions.
Immuron Limited furnished a Form 6-K to provide U.S. investors with copies of two announcements it filed with the Australian Securities Exchange. The announcements, dated December 16, 2025, are an Application for quotation of securities and a related Cleansing Notice, both attached as exhibits to the report.